STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0287
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Werner Milton H.

(Last)

(First)

(Middle)

3350 RIVERWOOD PARKWAY SE, SUITE 1900

(Street)

ATLANTA

30339

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.86⁽¹⁾	01/21/2025		D⁽²⁾			3,643⁽¹⁾	⁽³⁾	11/01/2025	Common Stock	3,643⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		3,643⁽¹⁾		⁽³⁾	11/01/2025	Common Stock	3,643⁽¹⁾	$0⁽²⁾	3,643⁽¹⁾	D
Stock Option (Right to Buy)	$13.86⁽¹⁾	01/21/2025		D⁽²⁾			3,643⁽¹⁾	⁽³⁾	11/01/2026	Common Stock	3,643⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		3,643⁽¹⁾		⁽³⁾	11/01/2026	Common Stock	3,643⁽¹⁾	$0⁽²⁾	3,643⁽¹⁾	D
Stock Option (Right to Buy)	$13.86⁽¹⁾	01/21/2025		D⁽²⁾			3,643⁽¹⁾	⁽³⁾	11/01/2027	Common Stock	3,643⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		3,643⁽¹⁾		⁽³⁾	11/01/2027	Common Stock	3,643⁽¹⁾	$0⁽²⁾	3,643⁽¹⁾	D
Stock Option (Right to Buy)	$28.76⁽¹⁾	01/21/2025		D⁽²⁾			3,643⁽¹⁾	⁽³⁾	11/01/2028	Common Stock	3,643⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		3,643⁽¹⁾		⁽³⁾	11/01/2028	Common Stock	3,643⁽¹⁾	$0⁽²⁾	3,643⁽¹⁾	D
Stock Option (Right to Buy)	$33.43⁽¹⁾	01/21/2025		D⁽²⁾			3,643⁽¹⁾	⁽³⁾	11/01/2029	Common Stock	3,643⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		3,643⁽¹⁾		⁽³⁾	11/01/2029	Common Stock	3,643⁽¹⁾	$0⁽²⁾	3,643⁽¹⁾	D
Stock Option (Right to Buy)	$60⁽¹⁾	01/21/2025		D⁽²⁾			16,667⁽¹⁾	⁽³⁾	12/22/2030	Common Stock	16,667⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		16,667⁽¹⁾		⁽³⁾	12/22/2030	Common Stock	16,667⁽¹⁾	$0⁽²⁾	16,667⁽¹⁾	D
Stock Option (Right to Buy)	$6.42⁽¹⁾	01/21/2025		D⁽²⁾			20,834⁽¹⁾	⁽³⁾	03/07/2029	Common Stock	20,834⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		20,834⁽¹⁾		⁽³⁾	03/07/2029	Common Stock	20,834⁽¹⁾	$0⁽²⁾	20,834⁽¹⁾	D
Stock Option (Right to Buy)	$4.44⁽¹⁾	01/21/2025		D⁽²⁾			35,000⁽¹⁾	⁽³⁾	03/01/2030	Common Stock	35,000⁽¹⁾	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		35,000⁽¹⁾		⁽³⁾	03/01/2030	Common Stock	35,000⁽¹⁾	$0⁽²⁾	35,000⁽¹⁾	D
Stock Option (Right to Buy)	$2.16	01/21/2025		D⁽²⁾			45,000	⁽³⁾	04/01/2031	Common Stock	45,000	$0⁽²⁾	0	D
Stock Option (Right to Buy)	$1.26	01/21/2025		A⁽²⁾		45,000		⁽³⁾	04/01/2031	Common Stock	45,000	$0⁽²⁾	45,000	D

Explanation of Responses:

1. The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.

2. The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

3. This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

	/s/ Milton H. Werner	01/22/2025
	** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.